Beyond HDL-C: The Lipid Profile Hiding Inside Metabolic Syndrome

HDL is not a molecule. It is a family of particles assembled from proteins and lipids, and its composition shifts with diet, inflammation, glucose handling and disease. Researchers have catalogued more than 280 proteins and over 300 lipid species across the HDL pool, a complexity the standard cholesterol assay was never designed to register. The systematic review by Grao-Cruces and colleagues set out to ask a narrower question: when someone has metabolic syndrome — the cluster of abdominal obesity, high blood pressure, dysglycemia and dyslipidemia — how does the lipid cargo inside their HDL particles differ from that of healthy controls?

After searching MEDLINE, the Cochrane Library and Web of Science under PRISMA guidelines, the authors found only four studies that met their eligibility criteria. That is a small evidence base, and it is worth saying so plainly. But within it, the signal was consistent. HDL particles in metabolic syndrome carried higher levels of triacylglycerides and phosphatidylinositol, alongside lower levels of several lipid families thought to support HDL's anti-inflammatory and cholesterol-efflux functions. In other words, the particle was remodeled — and not in a flattering direction — even when the HDL-C value on the lab report might look unremarkable.

For the reader on a GLP-1, or considering one, the practical takeaway is not that HDL-C is meaningless. It is that the heuristic of 'higher HDL-C equals lower risk' has limits, especially when metabolic syndrome is in the picture. Two people can share the same HDL-C and carry quite different HDL particles — one buoyant and functional, the other triglyceride-enriched and inflammatory. The review's authors argue that the functional properties and molecular components of HDL, rather than HDL-C alone, are likely the key determinants of cardiovascular risk in this population.

None of this changes what your clinician can order tomorrow. Lipidomic profiling is a research tool, not a routine blood test. But it does change how to interpret a 'normal-looking' panel in someone who otherwise carries the markers of metabolic syndrome: central adiposity, elevated fasting glucose, raised blood pressure, high triglycerides. The reassurance offered by a single HDL number, in that context, may be thinner than it appears.

The second study takes a different route into the same neighborhood. Drawing on the National Health and Nutrition Examination Survey from 2005 to 2018, Zhang and colleagues followed 9,283 adults diagnosed with hyperlipidemia and asked whether a non-invasive marker of insulin resistance — the estimated glucose disposal rate, or eGDR — predicted who lived and who did not. eGDR is calculated from waist circumference, hypertension status and HbA1c, so it is a composite picture of metabolic health rather than a fasting insulin draw.

The gradient was striking. In the lowest eGDR quartile — the most insulin-resistant group — all-cause mortality reached 13.08%, compared with 3.07% in the most insulin-sensitive quartile. Cardiovascular mortality showed a similar spread, 4.06% versus 0.48%. After adjustment, each one-unit increase in eGDR was associated with a 7% lower all-cause mortality risk and a 14% lower cardiovascular mortality risk. The signal was especially pronounced in adults under 60.

The most provocative finding is mediational. When the authors tested whether kidney function helped explain the eGDR–mortality link, estimated glomerular filtration rate accounted for roughly 36.5% of the association. That does not mean insulin resistance kills through the kidneys alone, but it does suggest the kidney is a meaningful node in the pathway that connects metabolic dysfunction to long-term outcomes in hyperlipidemic adults. For a reader whose attention has been trained on lipids and glucose, it is a useful nudge: renal function is part of the same story.

Caveats matter here. This is an observational analysis. eGDR is an estimate, not a clamp study. NHANES is a U.S. snapshot with its own demographic skew. And mediation analyses describe statistical relationships, not proven mechanisms. Still, the direction and magnitude of the gradient are hard to ignore, and they line up with a broader literature linking insulin resistance to cardiovascular and renal outcomes.

Honest framing: moderate. The HDL lipidome review synthesizes only four eligible studies — a thin foundation, even when the findings rhyme. The NHANES analysis is large and well-conducted but observational, which means it can describe associations but cannot prove that raising eGDR or protecting kidney function would, on its own, lower mortality. Both papers point in the same direction as a wider body of cardiometabolic research, but neither is the final word.

What they do offer, taken together, is a more honest picture of what a cholesterol panel can and cannot tell you. HDL-C is a useful screen, not a verdict. Insulin resistance and kidney function deserve to sit alongside it. And for anyone navigating metabolic syndrome — with or without a GLP-1 in the mix — the most informed conversation with a clinician is probably the one that treats lipids, glucose and renal health as a single system rather than three separate report cards.